German health minister in move to boost COVID drug Paxlovid use
The pill, which won conditional European marketing approval in January, is given to infected people who are at high risk of progression to severe illness.
Frankfurt: Germany's health minister said on Sunday he will push for more prescriptions of Pfizer's oral COVID-19 antiviral treatment Paxlovid by family doctors to reduce severe cases of the disease."A system involving family doctors will be prepared to administer this far too rarely-used COVID life saver more routinely," he wrote on Twitter on Sunday, adding that sufficient stockpiles...
Login or Register to read the full article
Frankfurt: Germany's health minister said on Sunday he will push for more prescriptions of Pfizer's oral COVID-19 antiviral treatment Paxlovid by family doctors to reduce severe cases of the disease.
"A system involving family doctors will be prepared to administer this far too rarely-used COVID life saver more routinely," he wrote on Twitter on Sunday, adding that sufficient stockpiles were available.
The pill, which won conditional European marketing approval in January, is given to infected people who are at high risk of progression to severe illness.
In his tweet, Lauterbach mentioned trial results that the oral treatment course can cut the risk of hospitalisation in the elderly by 90%, when taken early after infection.
Pfizer said on Thursday it is seeking full U.S. approval for Paxlovid, which is currently available under an emergency use authorization there.
Deaths and intensive care treatments after COVID infections have been on the rise again in Germany since late June, driven by more infectious subvariants of Omicron, after falling steadily for about three months.
The drug was not found to ease symptoms among younger adults.
German chancellor Olaf Scholz, a member of centre-left SPD like Lauterbach, on Sunday said schools and non-essential businesses would not be shut again if infection rates rose significantly this year, but that face masks would play a bigger role.
Read also: Pfizer seeks USFDA nod for COVID drug Paxlovid for high-risk patients
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd